Roche Enters Licensing Agreement With Sarepta Therapeutics for Gene Therapy

Date : 12/23/2019 @ 7:25AM
Source : Dow Jones News
Stock : Roche Holdings Ltd AG (QX) (RHHBY)
Quote : 39.89  -0.895 (-2.19%) @ 9:59PM
After Hours
Last Trade
Last $ 39.89 ◊ 0.00 (0.00%)

Roche Enters Licensing Agreement With Sarepta Therapeutics for Gene Therapy

Historical Stock Chart

3 Months : From Nov 2019 to Feb 2020

Click Here for more Roche (QX) Charts.
   By Cristina Roca 

Roche Holding AG (RO.EB) said Monday that it has struck a licensing deal with Sarepta Therapeutics Inc. (SRPT) for the exclusive right to launch and commercialize a gene therapy used for patients with Duchenne muscular dystrophy outside the U.S.

The Swiss pharmaceutical company said it will pay Sarepta an upfront $750 million in cash and $400 million in equity at closing, which is expected in the first quarter of 2020, for the rights to its SRP-9001 investigational gene therapy.

Sarepta is also eligible to receive regulatory and sales milestones of up to $1.7 billion, plus royalties on net sales, Roche said. The two companies will also share global development expenses.


Write to Cristina Roca at


(END) Dow Jones Newswires

December 23, 2019 02:10 ET (07:10 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.